FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Tissue Repair Ltd Stock AnalysisComprehensive stock analysis for Tissue Repair Ltd (TRP.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTRP.AX
TRP.AX
Tissue Repair Ltd
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TRP.AX
Home🔹Stocks🔹Tissue Repair Ltd

Tissue Repair Ltd

🇦🇺TRP.AX•ASX

Tissue Repair Ltd

🇦🇺TRP.AX•ASX
Sentiment

Your view on TRP.AX

Sentiment
Your view
TRP.AX
Tissue Repair Ltd
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TRP.AX
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Tissue Repair Ltd

Industry
Biotechnology
Sector
Healthcare
CEO
Tony Charara
Headquarters
Tower A, The Zenith, Chatswood, NSW, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Tony Charara
Headquarters
Tower A, The Zenith, Chatswood, NSW, AU
Description

Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing recovery following cosmetic procedures.

Its product pipeline features TR-987 and a suite of innovative dressings and matrices, including the proprietary Glucoprime technology. These are specifically engineered to address challenging conditions such as chronic wounds, burns, and other complex dermal injuries.

Additionally, TR Pro+ is being developed for post-procedure care after minimally invasive aesthetic treatments. Beyond these core programs, Tissue Repair is also exploring applications in animal health, novel bandage and scaffold technologies, and various other therapeutic areas.

The company was founded in 2012 and operates from its headquarters in Sydney, Australia.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Tissue Repair Ltd, and the rating behind it. TRP.AX last traded at AUD 0.08; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Tissue Repair Ltd. Starting points for Tissue Repair Ltd: EPS -AUD 0.09, beta 0.23 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Tissue Repair Ltd. Tissue Repair Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Tissue Repair Ltd. Trailing twelve-month EPS for Tissue Repair Ltd stands at -AUD 0.09. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Tissue Repair Ltd. Tissue Repair Ltd has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Tissue Repair Ltd valued side by side against its closest peers. Tissue Repair Ltd is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Tissue Repair Ltd, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Tissue Repair Ltd executives and directors. Shares of Tissue Repair Ltd have traded between AUD 0.06 and AUD 0.48 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Tissue Repair Ltd. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Tissue Repair Ltd. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Tissue Repair Ltd. Coverage tracks Tissue Repair Ltd within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • AT1.AX — Atomo Diagnostics Limited
  • AVE.AX — Avecho Biotechnology Limited
  • BTC.AX — BTC Health Limited
  • ENL.AX — Enlitic, Inc.
  • IMC.AX — Immuron Limited
  • NC6.AX — Nanollose Limited
  • NOX.AX — Noxopharm Limited

More Biotechnology companies

  • PHIO — Phio Pharmaceuticals Corp.
  • PHMMF — Pharma Mar, S.A.
  • PHRM.CN — PharmaTher Holdings Ltd.
  • PHRRF — PharmaTher Holdings Ltd.
  • PHVS — Pharvaris N.V.
  • PHYOF — IXICO plc
  • PKTX — ProtoKinetix, Incorporated
  • PLRX — Pliant Therapeutics, Inc.
  • PLRZ — Polyrizon Ltd.
  • PLUR — Pluri Inc.
  • PLX — Protalix BioTherapeutics, Inc.
  • PLYX — Polaryx Therapeutics, Inc. Common Stock

News

Latest Market News